RAF1 and neoplasm: Another potential mechanism underlying the effects of imatinib and nilotinib on motility-associated tyrosine phosphorylation is increased signalling through the RAF/MEK/ERK pathway, which has recently been reported to occur in several human tumour cell lines in response to these drugs3.